
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
2.78 (USD) • At close April 25, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Orchestra BioMed Holdings, Inc. |
Symbool | OBIO |
Munteenheid | USD |
Prijs | 2.78 |
Beurswaarde | 106,508,750 |
Dividendpercentage | 0% |
52-weken bereik | 2.49 - 8.87 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. David P. Hochman |
Website | https://orchestrabiomed.com |
An error occurred while fetching data.
Over Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)